Tuesday, June 10, 2014

Cancer drug developer Verastem published the book on the study of the loss of Merlin

Rick Kornak provides sharp news and interesting articles for the Mesothelioma Cancer Alliance. Bio.

Rick Kornak

May 29, 2014

Cambridge, Massachusetts --scientists working for the developer of drug Verastem, Inc. have published an article in the latest issue of the journal Science Translational Medicine, and the details of the study are source of inspiration for cancer patients, including those suffering from Mesothelioma.

The book, entitled, "Merlin deficiency predicts FAK inhibitor sensitivity: synthetic lethal relationship» details scientific findings related to merlin, a tumor suppressor. Results of the study showed that the loss of merlin increases the reactivity of the patient to drugs that target cancer stem cells by inhibition of focal adhesion kinase (FAK). Loss of Merlin is a common symptom of mesothelioma, with about half of the victims of the disease suffer from this deficiency.

According to Jonathan Pachter, Ph.d. and Director of research at Verastem, "these results based on key findings published earlier this year, which showed that the loss of merlin pushes the development of very aggressive malignant mesothelioma. Accordingly, in a model of tumor derived from patient negative merlin mesothelioma, FAK inhibitor treatment as maintenance therapy prolonged inhibition of tumor growth after treatment with pemetrexed [standard-care workers] and cisplatin. »

Mesothelioma is a fatal type of cancer that is caused by exposure to asbestos. Asbestos has been banned for the use for several decades, but there are still about 3,000 made mesothelioma diagnoses every year. The disease has a long latency period, so many of its victims were exposed to the carcinogenic material before the ban.

Share your ideas with us on Facebook


Cancer drug developer Verastem published the book on the study of the loss of Merlin

No comments:

Post a Comment